OLIGONUCLEOTIDE BASED THERAPIES FOR RARE GENETIC DISEASES
WE ARE HANUGEN THERAPEUTICS: a biopharmaceutical company focused on developing innovative oligonucleotide based therapeutics.
OUR GOAL is to use the power of Science to improve the lives of people affected by rare, infectious and other diseases.
OUR COMMITMENT to the patients and families impacted by rare diseases extends beyond treatment.
Making an Impact
Our novel chemistries allow us to address specific genetic diseases by altering the RNA transcription process and thereby modifying protein structure.
We specialize in modified oligos, fluorescent probes, long oligos and large scale oligo synthesis. The more modifications that are present in an oligo, and the longer the sequence, the more demanding the synthesis and purification.
About Us
We are committed to the rare disease community beyond the development of meaningful therapies.
We are dedicated to delivering advances in oligonucleotide based medicines.
Hanugen Therapeutics was established to provide high quality oligonucleotides. Oligonucleotides are now used in academic and commercial research in the fields of genetics, genomics, molecular biology, biochemistry, biotechnology and nanotechnology. We supply a wide range of custom-made unmodified and chemically modified oligonucleotides with high standards of quality assurance for small and large scale applications.
We interact with our customers before ordering, suggesting modifications that will give the best results, both in the synthesis of the oligo and in subsequent biochemical experiments. We welcome customer feedback.
Hanugen Therapeutics is committed in developing improved methods of oligonucleotide synthesis and for the design of superior modified oligos.
Hanugen Therapeutics is interested in establishing partnerships with companies and organisations with complementary interests. In the past, such partnerships with have been critical in the growth of several large biotech companies.
Please get in touch, with us.
Our Partners
